Allogene Therapeutics Inc... (ALLO)
NASDAQ: ALLO
· Real-Time Price · USD
1.17
-0.01 (-0.85%)
At close: May 30, 2025, 3:59 PM
1.20
2.95%
After-hours: May 30, 2025, 05:28 PM EDT
-0.85% (1D)
| Bid | 1.03 |
| Market Cap | 254.82M |
| Revenue (ttm) | -22K |
| Net Income (ttm) | -252.32M |
| EPS (ttm) | -1.22 |
| PE Ratio (ttm) | -0.95 |
| Forward PE | -1.17 |
| Analyst | Buy |
| Ask | 1.21 |
| Volume | 2,574,229 |
| Avg. Volume (20D) | 3,378,625 |
| Open | 1.18 |
| Previous Close | 1.18 |
| Day's Range | 1.10 - 1.21 |
| 52-Week Range | 0.86 - 3.78 |
| Beta | 0.60 |
About ALLO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ALLO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ALLO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
-15.68%
Allogene Therapeutics shares are trading lower aft...
Unlock content with
Pro Subscription
2 months ago
+0%
Allogene Therapeutics shares are trading lower after HC Wainwright & Co. cut its price target on the stock from $9 to $8.
2 weeks ago · seekingalpha.com
Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call TranscriptAllogene Therapeutics, Inc. (NASDAQ:ALLO ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Christine Cassiano - EVP, Chief Corporate Affairs & Brand Strategy Officer Davi...
2 months ago · seekingalpha.com
Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call TranscriptAllogene Therapeutics, Inc. (NASDAQ:ALLO ) Q4 2024 Earnings Conference Call March 13, 2025 5:00 PM ET Company Participants Christine Cassiano - EVP, Chief Corporate Affairs & Brand Strategy Officer Da...